Tumor Mutational Burden Subcommittee

The Tumor Mutational Burden (TMB) Subcommittee provides expert guidance and recommendations regarding scientific biology, technologies and practices relating to TMB as a quantitative genomic biomarker for personalized medicine in the cancer immunotherapy setting.

Chair

Jianda Yuan, MD, PhD

Merck Research Laboratories

Co-Chair

Priti S. Hegde, PhD
Genentech, Inc.